Pregabalin Should Not Be Used for Acute Anxiety Attacks in Pregnancy
Pregabalin is not appropriate for treating acute anxiety attacks during pregnancy and should be avoided. The FDA drug label explicitly states there are no adequate and well-controlled studies in pregnant women, and animal studies demonstrate significant developmental toxicity including skeletal malformations, growth retardation, and neurodehavioral abnormalities at clinically relevant exposures 1.
Evidence Against Pregabalin Use in Pregnancy
FDA Safety Data
The FDA label for pregabalin provides clear warnings about pregnancy risks 1:
- Animal studies show fetal structural abnormalities, skeletal malformations, and decreased fetal body weight at exposures ≥16 times human exposure at maximum recommended doses
- Offspring exposed during gestation and lactation demonstrated lethality, growth retardation, and nervous/reproductive system impairment
- No adequate human safety data exists
Recent Research Findings
Multiple high-quality studies from 2024-2025 raise serious concerns:
A 2024 systematic review found pregabalin exposure associated with 2:
- Increased risk of overall congenital anomalies
- Specific anomalies affecting nervous system, eyes, oro-facial clefts, urinary and genital systems
- Increased miscarriage and stillbirth risk
- Adverse neurodevelopmental outcomes
A 2025 Scottish population study of over 100,000 pregnancies demonstrated 3:
- Pregabalin strongly associated with pregnancy loss
- Developmental concerns significantly elevated (26.0% vs 15.7% in unexposed)
- Congenital conditions more common (2.7% vs 2.1%)
A 2024 multicenter case-control study found 4:
- Higher preterm delivery rates (18.5% vs 5.7%, p=0.04)
- Lower birth weight (22.2% vs 6.6%, p=0.016)
- Elevated major malformation rates (11% vs 4.5%, though not statistically significant)
Alternative Approaches for Acute Anxiety in Pregnancy
First-Line Non-Pharmacologic Interventions
For acute anxiety attacks during pregnancy, prioritize 5:
- Psychoeducation and self-management strategies - immediate implementation
- Cognitive behavioral therapy (CBT) - evidence-based for anxiety
- Mindfulness-based interventions (MBIs)
- Dialectical behavior therapy (DBT) techniques for acute distress
Pharmacologic Options If Absolutely Necessary
If non-pharmacologic approaches fail and medication is essential for maternal functioning 6, 7:
For acute anxiety episodes:
- SSRIs (sertraline, fluoxetine) - best safety profile in pregnancy, though not for immediate acute relief 8
- Short-term benzodiazepines - small but significant risk of birth defects; use only under specialist supervision for severe, disabling anxiety 6
- Avoid benzodiazepines in first trimester if possible due to teratogenic concerns
Important caveat: Benzodiazepines carry risks but have more established safety data than pregabalin. However, they should be reserved for severe cases under specialist guidance 6.
Clinical Decision-Making Algorithm
- Assess severity: Is the anxiety truly disabling and affecting daily functioning?
- Try non-pharmacologic first: CBT, mindfulness, self-management for 2 weeks minimum
- If medication required:
- Consult maternal-fetal medicine or psychiatry specialist
- Consider SSRIs for ongoing management (not acute relief)
- Reserve benzodiazepines for severe, acute episodes only under specialist care
- Never use pregabalin - insufficient safety data and concerning animal/human evidence
Key Pitfalls to Avoid
- Do not assume gabapentinoids are "safer" alternatives - the 2024 systematic review explicitly states combined evidence raises concerns about gabapentinoid safety in pregnancy 2
- Do not use pregabalin off-label for anxiety in pregnancy - it lacks both efficacy data for acute anxiety and safety data in pregnancy
- Do not delay specialist referral - anxiety requiring medication in pregnancy needs collaborative care with maternal-fetal medicine and psychiatry 7
Monitoring If Patient Already Taking Pregabalin
If a pregnant patient presents already taking pregabalin 1:
- Enroll in North American Antiepileptic Drug (NAAED) Pregnancy Registry (1-888-233-2334)
- Discuss risks vs. benefits of continuation with specialist
- Consider tapering and switching to safer alternatives
- Monitor fetal growth, blood pressure, and appropriate weight gain closely
- Arrange detailed fetal anatomy ultrasound
The evidence is clear: pregabalin should not be initiated for acute anxiety in pregnancy, and careful evaluation of benefit-risk balance is essential if a patient is already taking it when pregnancy is discovered.